AC Immune Showcasing Precision Medicine Programs at AAIC 2023
The presentations will include a poster detailing the design of the Phase 1b/2 ABATE trial evaluating the ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy in patients with Alzheimer’s disease and individuals with Down syndrome. In addition,
Perspectives Session symposium
TDP-43 proteinopathy in neurodegenerative diseases: current understanding of pathobiology and development of therapeutics and diagnostics
ID# 75520: Development of TDP-43 immunotherapy blocking transmission of seeding-competent species from ALS/FTD. (
ID# 75525: Discovery and optimization of the first-in-class TDP-43 PET tracer. (Tamara Seredenina, Ph.D.)
ID# 75830: An innovative clinical trial designed to evaluate the effects of ACI-24.060 in Alzheimer's Disease and in Down syndrome (ABATE Study)
Diagnostics & biomarkers
ID# 73125: Update on [18F]ACI-12589, a novel and promising PET-tracer for a-synuclein
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
|Head of Investor Relations & Corporate Communications
Phone: +41 21 345 91 91
Phone: +1 212 915 2577
Phone: +41 79 367 6254
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA